Payment overview · 2025
General Payments
$579.46
30 reported records · 8 companies
Healthcare provider profile · identity verified
Christopher Vlasek
Allopathic & Osteopathic Physicians|Family Medicine · CARSON CITY, NV · NPI 1518351089
Verified facts
What the public records show
CMS Open Payments records show Christopher Vlasek received $579.46 in general payments during 2025 across 30 reported records.
GlaxoSmithKline, LLC. accounted for 60.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $352.52 | 60.8% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.39 | 10.9% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $46.81 | 8.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.20 | 6.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.33 | 4.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.67 | 2.9% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $15.94 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.60 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $579.46 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $194.17 | 10 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $158.35 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.39 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $62.75 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
98 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
116 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 825 | 260 |
| Amlodipine Besylate | Amlodipine Besylate | 615 | 199 |
| Levothyroxine Sodium | Levothyroxine Sodium | 580 | 164 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 539 | 171 |
| Lisinopril | Lisinopril | 532 | 165 |
| Losartan Potassium | Losartan Potassium | 387 | 122 |
| Omeprazole | Omeprazole | 375 | 122 |
| Metformin Hcl | Metformin Hcl | 311 | 101 |
| Gabapentin | Gabapentin | 277 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 48 |
| Sertraline Hcl | Sertraline Hcl | 163 | 57 |
| Allopurinol | Allopurinol | 159 | 50 |
| Simvastatin | Simvastatin | 156 | 49 |
| Trazodone Hcl | Trazodone Hcl | 144 | 51 |
| Finasteride | Finasteride | 138 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 47 |
| Metformin Hcl Er | Metformin Hcl | 120 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 116 | 36 |
| Eliquis | Apixaban | 113 | 31 |
| Ezetimibe | Ezetimibe | 113 | 37 |
| Farxiga | Dapagliflozin Propanediol | 107 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 35 |
| Synthroid | Levothyroxine Sodium | 98 | 28 |
| Carvedilol | Carvedilol | 95 | 32 |
| Benazepril Hcl | Benazepril Hcl | 93 | 25 |
| Doxepin Hcl | Doxepin Hcl | 91 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 20 |
| Trulicity | Dulaglutide | 83 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 25 |
| Jardiance | Empagliflozin | 75 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 23 |
| Alendronate Sodium | Alendronate Sodium | 65 | 22 |
| Furosemide | Furosemide | 64 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 16 |
| Montelukast Sodium | Montelukast Sodium | 63 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 20 |
| Irbesartan | Irbesartan | 51 | 16 |
| Lovastatin | Lovastatin | 50 | 15 |
| Potassium Chloride | Potassium Chloride | 47 | 21 |
| Atenolol | Atenolol | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 14 |
| Glimepiride | Glimepiride | 43 | 12 |
| Meloxicam | Meloxicam | 43 | 21 |
| Buspirone Hcl | Buspirone Hcl | 42 | 13 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 42 | 16 |
| Prednisone | Prednisone | 38 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 32 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 11 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | 13 |
| Ozempic | Semaglutide | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 11 |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | 11 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Famotidine | Famotidine | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 17 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $579.46 · 30 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, DUPIXENT, NUCALA, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, VRAYLAR, VYEPTI, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error